Global Direct-to-consumer Genetic Testing Market Size, Status and Forecast 2019-2025 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: World Direct-to-consumer Genetic Testing Market

Direct-to-consumer (DTC) genetic testing is a type of genetic test that is accessible directly to the consumer without having to go through a health care professional. Usually, to obtain a genetic test, health care professionals (such as doctors) acquire their patient's permission and then order the desired test. DTC genetic tests, however, allow consumers to bypass this process and order DNA tests themselves.

Direct-to-consumer testing for BRCA mutations, as well as for mutations in other genes associated with various cancers, is currently available to individuals. As part of ancestry information, some companies provide BRCA gene mutation status based on microarray single nucleotide polymorphism (SNP) testing. However, this type of direct-to-consumer testing has not been validated for clinical use and generally does not provide genetic risk assessment. The NCCN does not recommend changes to a patient’s medical management based solely on direct-to-consumer testing results. The Food and Drug Administration (FDA) recommends that direct-to-consumer BRCA test results should not guide treatment; patients should have genetic counseling and confirmatory testing before any treatment decision is made.

The three specific BRCA1/BRCA2 breast cancer gene mutations are most common in people with Ashkenazi (Eastern European) Jewish ancestry, accounting for more than 90 percent of their risk of heritable breast and ovarian cancer. But even in this population, only 2 percent of women carry any of these three so-called founder mutations. Women with one of the mutations have a 45 percent to 85 percent chance of developing breast cancer by age 70.

In 2018, the U.S. FDA gave 23andMe the go-ahead to sell DNA tests assessing customers risk of 10 diseases, including Parkinson’s and late-onset Alzheimers. Those were the first FDA-approved direct-to-consumer tests for genetic risk of any disease or condition, which the agency said could help people make lifestyle decisions. At the time, the FDA also warned that genetic risk for complex diseases is not a sure thing.

The BRCA test is a part of 23andme’s $199 Health + Ancestry test. Existing customers can opt to receive BRCA information for no additional cost, and as with the other disease-risk tests they as well as new customers must specifically choose to receive the information.

In 2018, the global Direct-to-consumer Genetic Testing market size was 1078.3 million US$ and it is expected to reach 2998.3 million US$ by the end of 2025, with a CAGR of 15.7% during 2021-2026. This report focuses on the global Direct-to-consumer Genetic Testing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Direct-to-consumer Genetic Testing development in United States, Europe and China

Market Segmentation, Outlook & Viewpoint: World Direct-to-consumer Genetic Testing Market

Segmentation by Product Type: Breakdown of data from the year 2015 to 2020 and forecast until 2026:

 	
Diagnostic Screening
 	
Prenatal, Newborn Screening, and Pre-Implantation Diagnosis
 	
Relationship Testing

Segmentation by Product Type: Breakdown of data from the year 2015 to 2020 and forecast until 2026:

 	
Online
 	
Offline

Top Companies & Key Players: World Direct-to-consumer Genetic Testing Market

 	
23andMe
 	
MyHeritage
 	
LabCorp
 	
Myriad Genetics
 	
Ancestry.com
 	
Quest Diagnostics
 	
Gene By Gene
 	
DNA Diagnostics Center
 	
Invitae
 	
IntelliGenetics
 	
Ambry Genetics
 	
Living DNA
 	
EasyDNA
 	
Pathway Genomics
 	
Centrillion Technology
 	
Xcode
 	
Color Genomics
 	
Anglia DNA Services
 	
African Ancestry
 	
Canadian DNA Services
 	
DNA Family Check
 	
Alpha Biolaboratories
 	
Test Me DNA
 	
23 Mofang
 	
Genetic Health
 	
DNA Services of America
 	
Shuwen Health Sciences
 	
Mapmygenome
 	
Full Genomes

Key Insights Covered: World Direct-to-consumer Genetic Testing Market
1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue, and growth rate) of Direct-to-consumer Genetic Testing industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate, and gross margin) of Direct-to-consumer Genetic Testing industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue, and growth rate) of Direct-to-consumer Genetic Testing industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Direct-to-consumer Genetic Testing industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Direct-to-consumer Genetic Testing industry.

Research Methodology: Global Direct-to-consumer Genetic Testing Market

 	
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
 	
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
 	
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.